查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球疣治療市場
市場調查報告書
商品編碼
1140719

2022-2029 年全球疣治療市場

Global Warts Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

2021 年疣治療市場價值 19.1425 億美元。預計在預測期內（2022-2029 年）將以 4.90% 的複合年增長率增長。

疣是由人乳頭瘤病毒 (HPV) 引起的皮膚生長。它可能會持續數年並在治療後在相同或不同的區域復發。影響復發的因素似乎與患者的全身免疫狀態和局部因素有關。 HPV 有 60 多種類型，其中一些容易引起皮膚疣。

這些通常表現為皮膚上的粗糙腫塊，具有各種形狀和大小。可以在手肘、手指、膝蓋、面部、頭皮、腳底等部位進行。它通常發生在手背和手指上。足底疣很痛苦，會使行走變得困難。扁平疣可以大量出現在身體的任何部位。生殖器疣是影響人類的最常見的性傳播疾病 (STD)。

預計局部治療可在數週內消除疣，且副作用最小。局部治療並不總是有效的。因此，液氮冷凍療法是一種合適的治療選擇，治愈率在 60% 到 90% 之間，復發率在 20% 到 <10% 之間。

如今，病毒性疣、板狀疣和足底疣變得越來越普遍，可以使用現代激光設備和冷凍療法進行治療。這些可以用二氧化碳激光或射頻手術切除。

市場動態

全球疣治療市場的增長受到諸如疣患病率上升和治療劑研發增加等因素的推動。

疣和 HPV 感染率上升推動市場增長

疣是一種常見的皮膚病，可能會自發消退。外用鬼臼毒素治療尖銳濕疣的複發率在 6% 到 100% 之間。根據美國疾病控制和預防中心 (CDC) 的說法，三個月內生殖器疣的複發是典型的。因此，疣復發率的增加導致產品和治療的利用率增加，從而推動了疣治療市場。大約 10% 的兒童和青少年總是有疣。此外，據說有22%的孩子在童年時期會感染疣。

疣是由屬於人乳頭瘤病毒 (HPV) 家族的病毒引起的常見皮膚病感染。 HPV病毒在角蛋白中過度快速增殖，角蛋白是皮膚表面的一種硬蛋白。例如，根據肛門癌基金會的數據，美國每年估計有 1400 萬人感染 HPV。根據美國疾病控制和預防中心 (CDC) 的數據，美國每年約有 340,000 至 360,000 名女性和男性感染 HPV 生殖器疣。因此，疣和HPV感染的日益流行正在推動疣治療市場的增長。

缺乏認識導致的低診斷率阻礙了疣治療市場的增長

疣治療市場的全球增長可能會因缺乏對診斷的認識導致報告病例數少而受到阻礙，這反過來又會使治療選擇變得不那麼重要。然而，雖然疣的患病率很高，但患者的診斷率卻很低。例如，根據 2018 年健康保護報告，與 2014 年相比，在英格蘭參加性健康服務的 15-17 歲女孩的尖銳濕疣發病率下降了 92%。

流行病學

疣可以影響任何人，但已知有幾個流行病學變量。某些年齡組容易長疣。 9至16歲的風險最大。男性為 14.5 歲，女性為 13 歲。只有性活躍的人有患尖銳濕疣的風險。使用生肉工作的人特別容易患肉瘤。由於尚未在動物組織中發現 HPV，因此屠夫疣被認為是由職業創傷引起的，可能與工作時的寒冷潮濕環境相結合。

在美國 2017 年至 2027 年的流行病學、歷史和前瞻性流行病學（不同疣診斷的總數、按性別劃分的生殖器疣病例數、按年齡劃分的病例數、與 GW 相關的 HPV 類型、疣解剖）目標地點）。

管道分析

在全球範圍內，疣的流行率正在上升，促使市場參與者專注於研發並進入戰略發展以開發治療疣的新藥。例如

VP-102目前處於II期，用於治療皮膚科最常見的三種病毒性皮膚病：傳染性軟疣、普通疣和外生殖器疣。 .

Verrica 打算開發 VP-103，一種第二種候選斑蝥素，用於治療足底疣，一種人乳頭瘤病毒 (HPV) 皮膚感染。

Novan 正在開發 SB206 作為外用抗病毒凝膠，用於治療外生殖器疣。 SB206處於2期臨床試驗中。

COVID-19 影響分析

COVID-19 正在影響全球經濟，直接影響生產和需求、供應鏈中斷和市場中斷，以及對企業和金融市場的財務影響。

儘管大多數國家/地區都放寬了封鎖限制，但人們仍然不願親自去看醫生，因為擔心會傳播冠狀病毒 (COVID-19)。因此，疣治療市場的公司在 COVID-19 時代擁抱遠程醫療，因為個人更喜歡遠程醫療服務。在預測期內，對遠程醫療技術的需求將急劇上升。遠程醫療應用程序正在幫助加快疣護理領域的優質護理過程。

迫切需要減少臨床醫生和患者之間的社交距離，這推動了疣治療領域對遠程醫療服務的需求。由於美國有大量活躍的 COVID-19 病例，預計遠程醫療服務在流行期間將以較大的複合年增長率增長。預計這將在預測期內推動疣治療市場。

細分分析

全球疣治療市場分為疣類型、治療類型和最終用戶。

按類型劃分，普通疣主導全球疣治療市場

根據疣的類型，全球疣治療市場分為普通疣、生殖器疣、扁平疣、足底疣等。普通疣是由人乳頭瘤病毒 (HPV) 引起的皮膚病毒感染。病毒迅速使皮膚外層的細胞增殖。它通常可以在手或手指上完成。據說學生容易感染尋常疣，因為他們經常在學校或大學與多人接觸。根據許多科學期刊，普通疣是最常見的疣類型之一。

按治療類型，物理破壞正在迅速增長

按治療類型，物理中斷部分預計將在預測期內以最快的增長率增長。物理破壞，如液氮冷凍療法，是治療尖銳濕疣等普通疣的一線治療方法，治愈率達 50% 至 80%。冷凍療法（冷凍療法、液氮療法）——一種通過在疣下方和周圍形成水泡來冷凍疣的方法。冷凍療法是一種冷凍疣（液氮）的方法，使疣和周圍的皮膚自然脫落。

高頻是用高頻設備或電極切割疣組織或破壞疣。

激光手術通常用於難以治療的病例。可能需要一種或多種治療方法或一種以上的治療方法來解決問題。

由於水楊酸具有成本效益，它可以改善臨床結果。

對於疣治療的需求不斷增長，這種治療在治療後不會留下疤痕並提供針對 HPV 的終生免疫力。因此，疣治療市場的公司越來越關注冷凍療法、組織角質溶解和免疫療法，以改善患者的治療效果。組織角質松解含有水楊酸，是疣藥物的一種流行的非處方 (OTC) 選擇。這很明顯，因為化學破壞治療選項水楊酸預計在預測期內將在疣治療市場實現指數級收入增長。

區域分析

按地區劃分，全球疣治療市場分為北美、歐洲、亞太地區、拉丁美洲、中東和非洲。

北美有望主導全球疣治療市場

到 2021 年，北美將佔據全球疣治療市場的最大市場份額。預計這一趨勢將在預測期內持續。據推測，該地區對不同治療方案的認識和新產品的推出將促進北美疣治療市場的增長。普通疣的患病率為 2200 萬男性和女性，每年診斷出的比例超過 8%。

遠程醫療的上升趨勢正在導緻美國疣治療市場發生重大轉變。例如，2019 年 12 月，總部位於加州的虛擬護理提供商 GenieMD 推出了一款名為 iVisit 的遠程醫療應用程序，以幫助將生殖器疣患者與合格的醫生聯繫起來進行虛擬就診。此類產品創新正在推動疣治療市場的增長。

競爭格局

疣治療市場的主要參與者正在加緊研發工作，為未感染 HPV 的患者開發改進的疫苗配方。製造商正在提高生產能力，以開發有助於有效治療生殖器疣的處方藥膏和凝膠。

主要參與者正在採取多種增長策略，包括產品發布、收購和合作夥伴關係，為全球疣治療市場的增長做出了貢獻。

貝瑞卡製藥

概述

Verrica Pharmaceuticals 成立於 2013 年，總部位於美國。 Verrica Pharmaceuticals, Inc. 是一家皮膚病治療公司，為需要醫療干預的皮膚病開發藥物。我們專注於皮膚病療法的開發和商業化。該公司的 VP-102目前正在進行臨床試驗，用於治療普通和外生殖器疣。

管道產品。

VP-102目前處於II期臨床試驗中，用於治療傳染性軟疣、普通疣和外生殖器疣，這是醫學皮膚科最常見的病毒性皮膚病。正在進行中。

Verrica 計劃開發 VP-103，這是第二種候選斑蝥素藥物裝置，用於治療足底疣，一種人乳頭瘤病毒 (HPV) 皮膚感染的足底。

主要發展。

2021 年 3 月，Torii 獲得了 Verica 的傳染性軟疣和尋常疣治療候選藥物在日本的獨家開發和商業許可。根據該許可協議，Torii 支付了 1200 萬美元的預付款。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按疣類型劃分的市場細分
  • 按治療類型劃分的市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 疣的發病率增加
    • 限制因素
      • 嚴格的監管審批
    • 機會
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 管道分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 保險報銷分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按疣類型

  • 常見的疣
  • 扁平疣（扁平疣）
  • 蹠疣（蹠疣）
  • 尖銳濕疣（尖銳濕疣）
  • 其他（甲週疣、絲狀疣、馬賽克疣等）

第 8 章按治療類型

  • 物理破壞
    • 冷凍療法（冷凍）
    • 手術切除
    • 激光治療
    • 其他
  • 藥物治療
    • 化學破壞
      • 博來黴素（病灶內）
      • 斑蝥素 (VP-102)
      • 水楊酸
      • 其他
    • 免疫調節劑
      • 咪奎莫特 5% - 外用
      • 干擾素 - 外用
      • 二硝基氯苯-外用劑
      • 容易出現局部差異
      • 類維生素A - 局部或口服
      • 其他
    • 疫苗
      • 9價人乳頭瘤病毒疫苗（Gardasil 9）
      • 宮頸癌
    • 角質層分離劑
      • 鬼臼樹脂（podcon-25、podoven-25、鬼臼樹脂）
      • 鬼臼 (Condilox)
      • 三氯乙酸外用製劑（三氯）
      • 5-氟尿嘧啶（Fdex、Fluoroplex）
      • 其他
    • 兒茶素（貝勒根）
    • 其他

第 9 章，最終用戶

  • 醫院
  • 診所
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 12 章公司簡介

  • 默克公司
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Dr. Scholl's
  • Mylan N.V.
  • Novan Inc.
  • Pfizer, Inc.
  • GlaxoSmithKline plc,
  • Teva Pharmaceutical Industries Ltd
  • Verrica Pharmaceuticals
  • Phio Pharmaceuticals Corp.
  • AIM ImmunoTech, Inc.（List Not Exhaustive）

第13章 DataM

簡介目錄
Product Code: DMPH2825

Market Overview

Warts Therapeutics Market was valued at USD 1914.25 Million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 4.90% during the forecast period (2022-2029).

Warts are skin growth that is caused by the human papillomavirus (HPV). It may persist for years and recurs at the same or different sites, even after treatment. Some factors influencing recurrence appear to be related to the patient's overall immune status and local factors. There are more than 60 types of HPV and some of which tend to cause warts on the skin.

These commonly appear as rough elevations on the skin and are of different shapes and sizes. One can notice them on elbows, fingers, knees, face, scalp and soles of the feet. These generally occur on the backs of the hands and the fingers. Foot wart causes a lot of pain and makes it difficult to walk. Flat warts occur in large numbers in any part of the body. Genital warts are the most common sexually transmitted diseases (STD) affecting people.

Topical treatments could predictably resolve warts in a few weeks with minimal side effects. Topical treatment may not be effective all the time. Hence, cryotherapy with liquid nitrogen is a suitable option for treatment, where the cure rate is 60% to 90% with less than 20% to 10% recurrence rate.

Viral, flat & plantar warts are widespread can be treated nowadays with the latest lasers equipment & cryotherapy. These can be surgically removed by co2 lasers & radiofrequency.

Market Dynamics

The global warts therapeutics market growth is driven by factors such as the rising prevalence of warts and increasing research & development for treatment drugs.

Rising Prevalence of Warts & HPV Infections is Driving the Market Growth

Warts are a common skin disorder that may regress spontaneously. The recurrence rate for genital warts treated with topical podophyllotoxin treatments is 6% to 100%. A to the Centers for Disease Control and Prevention (CDC), the recurrence of anogenital warts within three months is typical. Thus, an increase in the recurrence rate of warts leads to an increase in the utilization of products and treatment and this drive the market for warts therapeutics. About 10% of children and adolescents have warts at any one time. As many as 22% of children will contract warts during childhood.

Wart is a common dermatological infectious disorder caused by a virus that belongs to the Human Papilloma Virus (HPV) family. HPV viruses cause excessive and rapid growth of keratin, a hard protein on the top layer of the skin. For instance, as per the Anal Cancer Foundation, an estimated 14 million people are infected with HPV in the U.S. every year. According to the Centers for Disease Control and Prevention (CDC), in the U.S., around 340,000 to 360,000 women and men are affected annually by genital warts caused by HPV. Hence, an increase in the prevalence of warts & HPV infections drives the warts therapeutics market growth.

Low Diagnostic Rate Owing to Lack of Awareness is Hampering the Growth of the Warts Therapeutics Market

The global warts therapeutics market growth is likely to be hampered by the lack of awareness of the diagnosis leading to fewer reported cases and subsequently, leads to less significance for treatment options. However, the prevalence of warts is higher, but the diagnosis rate is low in patients. For instance, as per the Health Protection Report in 2018, the rate of genital warts diagnosis among girls aged 15 to 17 years in England, attending sexual health services decreased by 92% as compared to that in 2014.

Epidemiology

While warts can affect anyone, a few epidemiological variables are known. Certain age groups are more prone to warts. Those ages 9 to 16 years are at the highest risk. The peak age is 14.5 years for males and 13 years for females. Only those who are sexually active are at risk of genital warts. People who work with raw meat are at particularly high risk of butcher's warts. Since HPV has not been found in the tissues of the animals, butcher's warts are thought to be caused by occupational trauma, perhaps combined with the cold and moist conditions under which the job is performed.

The epidemiology will provide historical and forecasted epidemiology (Total Diagnosed Incidence of different warts, Gender-specific Cases, Age-specific Cases of Genital Warts, HPV type associated with GWs and Anatomical Location of Warts) in the United States from 2017-2027.

Pipeline Analysis

Globally, the prevalence of warts is rising, which encourages the market players to enter into strategic development, focusing on research and development to develop new drugs for warts treatment. For instance,

VP-102 currently in Phase II is for the treatment of molluscum contagiosum (molluscum), common warts and external genital warts, three of the most common viral skin diseases in medical dermatology.

Verrica intends to develop VP-103, a second cantharidin-based drug-device product candidate for the treatment of plantar warts, a skin infection on the bottom of the foot caused by the human papillomavirus (HPV)

Novan, Inc. is in the development of SB206 as a topical antiviral gel for the treatment of external genital warts. SB206 is in clinical trial phase 2.

COVID-19 Impact Analysis

The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets.

Lockdown regulations have been relaxed in most countries, but people are reluctant to visit doctors in person, due to the fear of spreading coronavirus (COVID-19). Thus, companies in the warts therapeutics market are adopting telemedicine as individuals prefer remote healthcare services amidst the COVID-19 era. The demand for telehealth technology will rise dramatically during the forecast period. Telemedicine apps are helping to expedite the process of quality medical care in the sphere of warts therapeutics.

The emergency need for social distancing among clinicians and patients has catalyzed the demand for telemedicine services in the domain of warts therapeutics. Due to the high prevalence of active COVID-19 cases in the United States, telemedicine services are expected to grow at a significant CAGR during the pandemic. This is expected to drive the warts therapeutics market during the forecast period.

Segment Analysis

The global warts therapeutics market is segmented into wart type, treatment type, and end-user.

By Type, Common Warts Dominate the Global Warts Therapeutics Market

Based on warts type, the global warts therapeutics market has been classified into common warts, genital warts, flat warts, plantar warts, and others. The common wart is a cutaneous viral infection caused by human papillomavirus (HPV). This virus causes the rapid growth of cells on the outer layer of your skin. It usually grows on your hands or fingers. Students are more prone to acquiring common warts, owing to increased chances of contact with multiple individuals in schools and colleges. According to numerous published journals, among different warts, common warts are a highly common type of warts.

Based on Treatment Type, Physical Destruction is the Fastest Growing Segment

By treatment type, the physical destruction segment is expected to grow at the fastest growth rate over the forecast period. Physical destruction, such as cryotherapy (freezing) with liquid nitrogen, represents the first line of therapy treatment for warts such as genital warts, common warts which provide cure rates of 50% to 80%. The Freezing (Cryotherapy, or Liquid Nitrogen Therapy)-Freezing works by causing a blister to form under and around your wart. Cryosurgery involves freezing the wart (liquid nitrogen), after which the wart and the surrounding skin fall off by themselves.

Radiofrequency involves cutting away the wart tissue or destroying it by radiofrequency device or electrodesiccation.

Laser Surgery is usually reserved for tough-to-treat cases. More than one treatment or more than one approach to treatment may be necessary to manage the problem.

Salicylic Acid Improves the Clinical Outcomes Owing to Cost-Efficiency

There is a rising demand for wart treatment that offers no scarring post-treatment and provides a lifetime of immunity against HPV. Thus, companies in the warts therapeutics market are increasing their focus on cryotherapy, tissue keratolysis, and immunotherapy to increase patient outcomes. Tissue keratolysis involves salicylic acid and is popular in over-the-counter (OTC) options for warts therapeutics. This is evident since salicylic acid, is a chemical destruction treatment option, is expected to register exponential revenue growth in the warts therapeutics market during the forecast period.

Geographical Analysis

In terms of region, the global warts therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America is Expected to Dominate the Global Warts Therapeutics Market

North America accounted for the largest market share of the global warts therapeutics market in 2021. This trend is expected to continue during the forecast period. The growing awareness towards different treatment options and the launch of new products in this region are estimated to boost the warts therapeutics market growth in North America. The prevalence of common warts is 22 million among men and women, and more than 8% are diagnosed annually.

The growing trend of telemedicine is making a significant change in the warts therapeutics market in the United States. For instance, in December 2019, GenieMD, a California-based virtual care delivery company, launched a telemedicine app called iVisit, which helps to connect genital warts patients with the best physicians through a virtual visit. Such product innovations are boosting the growth of the warts therapeutics market.

Competitive Landscape:

Some of the major players in the schistosomiasis treatment market include Merck & Co., Inc., Dr Scholl's, Mylan N.V., Novan Inc., Pfizer, Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Verrica Pharmaceuticals, Phio Pharmaceuticals Corp., AIM ImmunoTech, Inc., among others. The major players in the market of warts therapeutics are increasing their R&D to develop improved formulations of vaccines for patients who have not been previously vaccinated against HPV. Manufacturers are increasing their production capabilities to develop prescription creams and gels that help to effectively treat genital warts.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the warts therapeutics market globally.

Verrica Pharmaceuticals

Overview:

Verrica Pharmaceuticals, founded in 2013 and is headquartered in the United States. Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. It is specialized in the development and commercialization of dermatological treatments. Currently, the company's VP-102 is in the clinical trial phase for common and external genital warts indication.

Pipeline Products:

VP-102 currently in Phase II is for the treatment of molluscum contagiosum (molluscum), common warts and external genital warts, three of the most common viral skin diseases in medical dermatology.

Verrica intends to develop VP-103, a second cantharidin-based drug-device product candidate for the treatment of plantar warts, a skin infection on the bottom of the foot caused by the human papillomavirus (HPV)

Key Developments:

In March 2021, Torii acquired the exclusive license to develop and commercialize Verrica's product candidates for the treatment of molluscum contagiosum and common warts in Japan. Under the license agreement, Torii made up-front payments of $12.0 million.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Wart Type
  • 3.2. Market Snippet by Treatment Type
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising incidence of Wart
      • 4.1.1.2. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent regulatory approvals
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Pipeline Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Wart Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type Segment
    • 7.1.2. Market Attractiveness Index, By Wart Type Segment
  • 7.2. Common wart (verruca vulgaris)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3. Flat wart, or plane wart (verruca plana)
  • 7.4. Plantar wart, or verruca (verruca plantaris)
  • 7.5. Genital wart (condyloma acuminatum)
  • 7.6. Others( Periungual wart, Filiform wart, Mosaic warts)

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
    • 8.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 8.2. Physical Destruction*
    • 8.2.1.
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.2.2. Cryotherapy (Freezing)
    • 8.2.3. Surgical Removal
    • 8.2.4. Laser Treatment
    • 8.2.5. Others
  • 8.3. Medication
    • 8.3.1. Chemical Destruction
      • 8.3.1.1. Bleomycin intralesional
      • 8.3.1.2. Cantharidin (VP-102)
      • 8.3.1.3. Salicylic Acid
      • 8.3.1.4. Others
    • 8.3.2. Immunomodulatory agent
      • 8.3.2.1. Imiquimod 5% - topical
      • 8.3.2.2. Interferon - intralesional
      • 8.3.2.3. Dinitrochlorobenzene - topical
      • 8.3.2.4. Diphencyprone topical
      • 8.3.2.5. Retinoids - topical or oral
      • 8.3.2.6. Others
    • 8.3.3. Vaccines
      • 8.3.3.1. Human papillomavirus vaccine, nonavalent (Gardasil 9)
      • 8.3.3.2. Cervarix
    • 8.3.4. Keratolytics
      • 8.3.4.1. Podophyllum resin (Podocon-25, Podo-Ben-25, Podofin)
      • 8.3.4.2. Podofilox (Condylox)
      • 8.3.4.3. Trichloroacetic acid topical (Tri-Chlor)
      • 8.3.4.4. 5-Fluorouracil (Efudex, Fluoroplex)
      • 8.3.4.5. Others
    • 8.3.5. Kunecatechins (Veregen)
    • 8.3.6. Other

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User Segment
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 9.3. Clinics
  • 9.4. Others

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.7.1. Brazil
      • 10.6.7.2. Argentina
      • 10.6.7.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Merck & Co., Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Dr. Scholl's
  • 12.3. Mylan N.V.
  • 12.4. Novan Inc.
  • 12.5. Pfizer, Inc.
  • 12.6. GlaxoSmithKline plc,
  • 12.7. Teva Pharmaceutical Industries Ltd
  • 12.8. Verrica Pharmaceuticals
  • 12.9. Phio Pharmaceuticals Corp.
  • 12.10. AIM ImmunoTech, Inc. (List Not Exhaustive)

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us